Merck KGaA · XETR:MRK

Merck KGaA — J.P. Morgan Healthcare Conference 2013

26 slides from Merck KGaA's conference presentation, Jan 7, 2013

  1. Slide 1: Merck KGaA, Darmstadt, Germany

    Merck KGaA, Darmstadt, Germany J.P. Morgan Healthcare Conference 2013 Matthias Zachert Stefan Oschmann Chief Financial Officer CEO Biopharmaceuticals San Francisco, January 7, 2013

  2. Slide 2: Publication of Merck KGaA, Darmstadt, Germany

    Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

  3. Slide 3: Disclaimer

    Disclaimer Remarks All comparative figures relate to the corresponding last year’s period. Important information This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares referred to herein have not bee

  4. Slide 4: Agenda

    Agenda  Business overview  Transforming the company  Biopharmaceuticals update

  5. Slide 5: Balanced portfolio of four divisions

    The Group Balanced portfolio of four divisions Divisional sales and operating profitability Margin1 Life Life Science Tools 20% 23.5% Biopharmaceuticals Science Tools 24% Performance Materials 23% 43.3% Consumer Health 12.7% 56% 16% Biopharmaceuticals 55% 28.8% Performance 4% Materials Consumer Heal

  6. Slide 6: Geographically diverse business

    The Group Geographically diverse business Sales by region [%] North America Europe 20% 37% 34% 9% Emerging Markets Rest of World* Strong presence in Emerging Markets * Africa, Australia, Japan Sales split based on YTD Sept 12 sales 6 5

  7. Slide 7: We have added scale while strengthening the attractiveness of assets in our portfolio

    The Group We have added scale while strengthening the attractiveness of assets in our portfolio 2002 Revenues €7.5 bn Transaction volume 2011 Revenues €10.3 bn Laboratory Millipore Life Science Tools Distribution Divestments Life Science Products Performance Materials Analytics & Reagents CropBiosci

  8. Slide 8: Our stronger portfolio has enabled us to fundamentally improve our profitability

    The Group Our stronger portfolio has enabled us to fundamentally improve our profitability Group total revenues and adjusted EBIT margin* 2002-2011 Acquisition of Millipore Acquisition of Serono adj. EBIT €m 10,276 margin* Divestment of Generics 10,000 9,291 7,747 30% 8,000 7,473 7,558 7,202 7,057 6

  9. Slide 9: Agenda

    Agenda  Business overview  Transforming the company  Biopharmaceuticals update

  10. Slide 10: Portfolio evolution improved our profitability structure, but further potential remains

    Transforming the company Portfolio evolution improved our profitability structure, but further potential remains Assessment of long-term financial performance relative to peers Gross R&D Sales growth SG&A margin productivity Biopharmaceuticals Consumer Health Performance Materials Life Science Tools

  11. Slide 11: We now focus on efficiency

    Transforming the company We now focus on efficiency Transformation process 2012-2018 2012 2013 2014 2015 2016-18 Efficiency  De-complex organization  Optimize cost structure  Increase R&D productivity Organic growth  Exploit leading market positions  Execute selected bolt-on acquisitions Portfo

  12. Slide 12: New management in key positions and across the entire organization

    Transforming the company New management in key positions and across the entire organization Management changes Divisions Biopharmaceuticals Corporate Head of Head of Biopharma- Head of Head of ceuticals Biopharma- Head of Consumer Life Science Corporate Chief Operating ceuticals Corporate HR Health

  13. Slide 13: Restructuring costs and net savings targets

    Transforming the company Restructuring costs and net savings targets Net annual savings [€m] 2012 2013 2014 2015 2016 2017 Total savings Biopharmaceuticals 50 200 300 300 Consumer Health 5 15 25 25 Life Science Tools 10 30 40 40 One-time costs [€m] Total savings of 2012 2013 2014 2015 € 365 million

  14. Slide 14: 9M 2012: Execution drives solid numbers

    Transformation shows first results 9M 2012: Execution drives solid numbers [€ m] 9M 2012 9M 2011 Δ Comments Sales 8,029 7,381 9%  9.0% sales growth reflects 4.1% organic growth, 4.3% EBITDA pre 2,175 2,043 6% FX benefit and 0.4% growth Margin (% of sales) 27.1% 27.7% from acquisitions  EBITDA pre

  15. Slide 15: Striving for realistic Group targets

    The Group Striving for realistic Group targets Mid-term targets Sales (€m) EBITDA pre (€m) EPS pre (€) +4% - 8% +10% - 17% +20% - 32% 10,350 - 10,700 3,000 - 3,200  €8.20 - €9.00 9,906 2,729 €6.83 2011 2014E 2011 2014E 2011 2014E 27.5%* 29% – 30%*  FX: EUR/USD = 1.35; EUR/CHF = 1.20 Assumptions

  16. Slide 16: Agenda

    Agenda  Business overview  Transforming the company  Biopharmaceuticals update

  17. Slide 17: Our business today

    Biopharmaceuticals Our business today Geographic sales diversification Lack of patent cliff North America Europe provides resilient revenue stream 22% 42% Portfolio of strong 29% brands continue to 7% generate growth Rest of World Emerging Markets Rebuilding the pipeline to provide for future growth

  18. Slide 18: Key products Rebif and Erbitux continue to be important assets

    Biopharmaceuticals – Global franchises Key products Rebif and Erbitux continue to be important assets Global quarterly sales [€m] 492 499 430  A standard in current multiple sclerosis (MS) treatment  Most prescribed MS treatment in many European markets 2011  Benefitting from positive pricing tre

  19. Slide 19: Despite patent expiry many of our products continue to grow

    Biopharmaceuticals – Global franchises Despite patent expiry many of our products continue to grow YTD Sept 12 global sales by franchise Fertility +15%* Endocrinology +12%* 53% 47% General Medicine flat* Rebif & Erbitux All other Biopharmaceuticals products Good franchises that continue to support t

  20. Slide 20: Rebuilding our pipeline with an emphasis on phase I and II projects

    Biopharmaceuticals – Pipeline Rebuilding our pipeline with an emphasis on phase I and II projects Phase I Phase II Phase III  Dominated by phase III projects, using up large parts of the resources L-BLP25 (NSCLC) Cilengitide (GBM)  Late-stage projects in non-core January ARX 201(GHD) Erbitux (aCC)

  21. Slide 21: L-BLP25 (Stimuvax): phase III START trial

    Biopharmaceuticals – Pipeline L-BLP25 (Stimuvax): phase III START trial L-BLP25: mode of action  START trial did not meet primary endpoint of  MUC1 antigen-specific prolongation of overall survival in patients with cancer immunotherapy Head-line unresectable, locally-advanced stage IIIA or IIIB re

  22. Slide 22: TH-302: first-in-class potential in oncology

    Biopharmaceuticals – Pipeline TH-302: first-in-class potential in oncology Proposed mode of action TH-302 Cell cycle Cancer cell Active drug (Prodrug) arrest death Oxygen-starved condition (e.g. tumor tissue) Phase III in soft tissue sarcoma (STS) Phase III in pancreatic cancer  Global trial, 450 p

  23. Slide 23: Upcoming pipeline newsflow

    Biopharmaceuticals – Pipeline Upcoming pipeline newsflow Project Indication Current phase Timing Event Head-line result Cilengitide Glioblastoma Phase III H1 2013 (CENTRIC) TH-302 Soft tissue sarcoma Phase III H1 2013 Futility analysis Phase III ‘go/no go’ ONO-4641 Multiple sclerosis Phase II 2013 d

  24. Slide 24: Alliance with Dr. Reddy's: entering growing biosimilars market

    Biopharmaceuticals – Biosimilars Alliance with Dr. Reddy’s: entering growing biosimilars market Rationale:  Biosimilars market is attractive  Focus on monoclonal antibodies in oncology  Co-development agreement of Merck KGaA, Darmstadt, Germany Experience in and Dr. Reddy’s + biosimilars  Co-pro

  25. Slide 25: Conclusion and mid-term targets

    Biopharmaceuticals Conclusion and mid-term targets Targets Diversified business providing Sales [€m] EBITDA pre [€m] resilient revenue +2% - 6% +15% - 21% stream 5,700 - 5,900 1,800 - 1,900 New globalized 5.564 1.569 R&D organization to increase efficiency and success rate Rebuilding the pipeline

  26. Slide 26: Merck KGaA

    Merck KGaA Darmstadt - Germany

Merck KGaA — J.P. Morgan Healthcare Conference 2013 on 6ix